Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.47 |
| ▸ | MC3R | P41968 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | MC1R | Q01726 | 2/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310545 | 0.99 | MC4R (0.48) | MC4RMC3RKCNH2LMNAHTT | |
| Lithium Ion SCHEMBL4917138 | 0.88 | MC4R (0.45) | MC4RMC3RKCNH2LMNAHTT | |
| SCHEMBL2307981 | 0.86 | KMT2A (0.49) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL14991591 | 0.84 | MC4R (0.50) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL18480949 | 0.84 | MC4R (0.55) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL15039511 | 0.83 | PANK3 (0.47) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL1920691 | 0.83 | PANK3 (0.47) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL12537050 | 0.81 | MC4R (0.67) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL29327373 | 0.81 | MC4R (0.67) | MC4RMC3RKCNH2MC5RMC1R | |
| SCHEMBL13493103 | 0.81 | MC4R (0.67) | MC4RMC3RKCNH2MC5RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | MC4R 1/4885MC3R 4/4885KCNH2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.